ANTI-ASTHMA DRUG OTC SWITCHES: DATA ON COURSE OF DISEASE
This article was originally published in The Tan Sheet
Executive Summary
ANTI-ASTHMA DRUG OTC SWITCHES: DATA ON COURSE OF DISEASE would be needed to support an Rx-to-OTC switch application, Nonprescription Drugs Advisory Committee Chairman Randy Juhl, PhD, University of Pittsburgh, concluded during a joint meeting of NDAC and the Pulmonary-Allergy Drugs Advisory Committee on Nov. 14. "I think the questions" raised during committee discussion of OTC marketing of asthma drugs "more revolve around the natural course of asthma than about the drug itself," Juhl commented. "I think those questions at this point are not overcomeable just by the drug itself. We really need to know more about asthma."